We have developed a proprietary gene therapy platform, the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which we believe there are no known effective treatments.

Our modified HSV-1 is a replication-deficient, non-integrating viral vector that can efficiently penetrate a broad range of skin cells. Its high payload capacity to accommodate large or multiple genes and low immunogenicity makes it a suitable choice for direct and repeat delivery to the skin.

Direct delivery

 

Non-integrating

 

Low immunogenicity

single virus 5

Significant and broad skin tropism

 

Regulatory precedent

 

Large payload capacity